Search research articles
Contact Us
Filters
Showing results (61-70 of 152) with videos related to
Page
of 16
Sort By:
Journal of Medicinal Chemistry
|
March 13, 2018
Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension
Morane Le Hiress, Bernardin Akagah, Guillaume Bernadat, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|
February 21, 2015
[Relevant issues in the pathology and pathobiology of pulmonary hypertension]
Rubin M Tuder, Stephen L Archer, Peter Dorfmüller, et al.
The European Respiratory Journal
|
February 25, 2012
Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension
Alice Huertas, Ly Tu, Natalia Gambaryan, et al.
Cardiovascular Research
|
July 13, 2020
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension
Marie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 24, 2015
Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex
Morane Le Hiress, Ly Tu, Nicolas Ricard, et al.
Circulation
|
April 12, 2006
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia
Saadia Eddahibi, Christophe Guignabert, Anne-Marie Barlier-Mur, et al.
Annals of the Rheumatic Diseases
|
August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
Jerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Pulmonary Circulation
|
December 5, 2019
Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure
Edda Spiekerkoetter, Elena A Goncharova, Christophe Guignabert, et al.
Metabolites
|
November 25, 2021
Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?
Thomas Duflot, Ly Tu, Matthieu Leuillier, et al.
Pharmacology & Therapeutics
|
October 19, 2013
Targeted therapies in pulmonary arterial hypertension
David Montani, Marie-Camille Chaumais, Christophe Guignabert, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 152) with videos related to
Sort By:
Page
of 16
Journal of Medicinal Chemistry
|
March 13, 2018
Design, Synthesis, and Biological Activity of New N-(Phenylmethyl)-benzoxazol-2-thiones as Macrophage Migration Inhibitory Factor (MIF) Antagonists: Efficacies in Experimental Pulmonary Hypertension
Morane Le Hiress, Bernardin Akagah, Guillaume Bernadat, et al.
Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|
February 21, 2015
[Relevant issues in the pathology and pathobiology of pulmonary hypertension]
Rubin M Tuder, Stephen L Archer, Peter Dorfmüller, et al.
The European Respiratory Journal
|
February 25, 2012
Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension
Alice Huertas, Ly Tu, Natalia Gambaryan, et al.
Cardiovascular Research
|
July 13, 2020
Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension
Marie-Camille Chaumais, Mohamed Reda Amar Djessas, Raphaël Thuillet, et al.
American Journal of Respiratory and Critical Care Medicine
|
July 24, 2015
Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex
Morane Le Hiress, Ly Tu, Nicolas Ricard, et al.
Circulation
|
April 12, 2006
Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia
Saadia Eddahibi, Christophe Guignabert, Anne-Marie Barlier-Mur, et al.
Annals of the Rheumatic Diseases
|
August 13, 2017
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
Jerome Avouac, Irena Konstantinova, Christophe Guignabert, et al.
Pulmonary Circulation
|
December 5, 2019
Hot topics in the mechanisms of pulmonary arterial hypertension disease: cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure
Edda Spiekerkoetter, Elena A Goncharova, Christophe Guignabert, et al.
Metabolites
|
November 25, 2021
Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?
Thomas Duflot, Ly Tu, Matthieu Leuillier, et al.
Pharmacology & Therapeutics
|
October 19, 2013
Targeted therapies in pulmonary arterial hypertension
David Montani, Marie-Camille Chaumais, Christophe Guignabert, et al.
Page
of 16